Pembrolizumab for Breast Cancer

Phase 1

Waitlist Available

Led By Donald W Northfelt

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a combination of two drugs for advanced breast cancer. It targets patients with a specific, hard-to-treat type of breast cancer. The drugs work by boosting the body's natural defenses against cancer and stopping cancer cell growth.

Eligible Conditions

Triple Negative Breast Cancer
Breast cancer
Bone Metastasis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Incidence of adverse events

Maximum tolerated dose

Secondary study objectives

Best response

Other study objectives

Assessment of PDJ amplification, PD-L1, PD-L2, JAK2 expression and pSTAT3

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (pembrolizumab, ruxolitinib phosphate)Experimental Treatment3 Interventions

Patients receive pembrolizumab IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

2017

Completed Phase 3

~2810

Ruxolitinib Phosphate

2011

Completed Phase 2

~390